Northeast Financial Consultants Inc Biogen Inc. Transaction History

Northeast Financial Consultants Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $60,838 - $73,919	-241 Reduced 7.35%	3,039 $841,000
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $104,834 - $124,668	-559 Reduced 14.56%	3,280 $669,000
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $11,655 - $18,661	-45 Reduced 1.16%	3,839 $1.33 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $178,028 - $245,992	809 Added 26.31%	3,884 $1.15 Million
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $10,002 - $11,218	-46 Reduced 1.47%	3,075 $716,000
Q2 2019 Aug 09, 2019	SELL	$219.29 - $241.72 $29,165 - $32,148	-133 Reduced 4.09%	3,121 $730,000
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $705,174 - $1.1 Million	3,254 New	3,254 $769,000
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $805,097 - $1.05 Million	-2,743 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $771,194 - $904,339	2,743	2,743 $859,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

Stay updated on Northeast Financial Consultants Inc with notifications on news.